Lancet Oncol?: Atezolizumab in combination with Capoplatinum and nab-paclitaxel for preoperative chemotherapy for non-small cell lung cancer

About 25% of non-small cell lung cancer patients have resusible ib-IIA disease, and although perioperative chemotherapy is the standard of treatment, this treatment strategy provides only modest benefitsBased on the activity of immunocheckpoint inhibitors in metastatic non-small cell lung cancer, the researchers looked at the activity of cabocein, nab-paclitaxel, and PD-L1 inhibitors atezolizumab as new complementary therapies prior to surgical removalthis study is a one-arm, Phase II study, conducted in the United StatesPatients aged 18 or over with restenable stage of IB-IIA non-small cell lung cancer are involvedDuring each 21-day cycle, patients receive intravenous injections of atezolizumab (1200 mg) on the first day, on the 1st, 8th and 15th days nab-paclitaxel (100 mg/m 2), on the first day of treatment of Caposplatin (5 mg/mL/min) and after 2 rounds of treatment, patients without progress continue to receive 2 rounds of treatment before being surgically removedThe main endpoint of the study was the primary pathological response, defined as the presence of 10% or less of residual tumor tissue at the time of surgery30 patients participated in the study, of which 23 (77%) were phased in phase IIIA, 29 (97%) had surgery and 26 (87%) successfully performed R0 excisionThe median follow-up period was 12.9 months, with 17 of the 30 patients (57%; 95% CI 37-75) having major pathological responsesThe most common treatment-related level 3-4 adverse events were a 50% reduction in neutropenocytic cells, an increase in the concentration of alanine amino transferase (7%), an increase in the concentration of amino transferase in winter, a 7% decrease in platelets (7%)Serious treatment-related adverse events included 1 case (3%) 3% reduction of stage 3 febrile neutrophils, 1 case (3%) 4 high blood sugar, 1 case (3%) level 2 bronchostoic pulmonary hemorrhage, no treatment-related deathsAtezolizumab combined with Capoplatinum and nab-paclitaxel therapy could be used as a new complementary treatment for preoperative chemotherapy for cut-off small cell lung cancer, with a high proportion of patients receiving pathological responses